Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration

Part of paid clinical trials in Chevy Chase, Maryland.

Sponsor
The National Retina Institute
Study ID
NCT00395707
Phase
PHASE1/PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Accepted

Interventions

Study Details

The primary objective of this study is to determine the safety \& efficacy of ranibizumab for the treatment of retinal angiomatous proliferation secondary to age related macular degeneration.

Key Dates

First listed
Nov 3, 2006
Start date
Aug 31, 2005
Status verified
Feb 2009
Primary completion
Apr 30, 2008
Completion
Apr 30, 2008

Study Design

Enrollment
20 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: 1
    Lucentis 0.3mg/0.05 ml
  • Active Comparator: 2
    Lucentis 0.5mg/0.05 ml

Primary Outcome Measure

Proportion of patients with stabilization of visual acuity, vision loss of < 15 letters [ Time Frame: 2 years ]

Locations (2)

FacilityCityStateZIPSite coordinators
National Retina InstituteChevy ChaseMaryland20815-
National Retina InstituteTowsonMaryland21204-

Find similar trials in Chevy Chase, MD

By condition
Age-related macular degeneration
By specialty
OphthalmologyRetina
By research site
National Retina Institute· Chevy Chase, MDNational Retina Institute· Towson, MD

Related Studies